| Title |
Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients
|
|---|---|
| Published in |
OncoTargets and therapy, June 2013
|
| DOI | 10.2147/ott.s44144 |
| Pubmed ID | |
| Authors |
Jinan Liu, Lizheng Shi, Oliver Sartor, Richard Culbertson |
| Abstract |
The most recent randomized controlled trial in a predominantly prostate-specific antigen-detected prostate cancer (PC) population found a nonsignificant reduction in mortality from radical prostatectomy (RP) compared to conservative management. The optimal treatment for clinically localized prostate cancer is anything but clear. The PC-specific mortality and all-cause mortality were compared between primary androgen-deprivation treatment (PADT) and RP, both as monotherapy, among clinically localized PC patients. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 26 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 15% |
| Other | 3 | 11% |
| Student > Postgraduate | 3 | 11% |
| Student > Master | 3 | 11% |
| Student > Doctoral Student | 2 | 7% |
| Other | 9 | 33% |
| Unknown | 3 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 44% |
| Unspecified | 1 | 4% |
| Mathematics | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 5 | 19% |
| Unknown | 6 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 December 2014.
All research outputs
#1,271,595
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#21
of 3,016 outputs
Outputs of similar age
#10,197
of 206,481 outputs
Outputs of similar age from OncoTargets and therapy
#1
of 45 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,481 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.